Literature DB >> 26667139

Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?

Janki Patel1, Cláudia M Salgado1, Miguel Reyes Múgica1, Dipanjan Basu1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26667139      PMCID： PMC4677422          DOI： 10.1093/neuonc/nov271

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  5 in total

1.  Druggable targets in pediatric neurocutaneous melanocytosis: Molecular and drug sensitivity studies in xenograft and ex vivo tumor cell culture to identify agents for therapy.

Authors:  Yibing Ruan; Anna Kovalchuk; Aarthi Jayanthan; Xueqing Lun; Yoji Nagashima; Olga Kovalchuk; James R Wright; Alfredo Pinto; Adam Kirton; Ronald Anderson; Aru Narendran
Journal:  Neuro Oncol       Date:  2014-11-12       Impact factor: 12.300

2.  Nevospheres from neurocutaneous melanocytosis cells show reduced viability when treated with specific inhibitors of NRAS signaling pathway.

Authors:  Dipanjan Basu; Cláudia M Salgado; Bruce S Bauer; Donald Johnson; Veronica Rundell; Marina Nikiforova; Yasmin Khakoo; Lorelei J Gunwaldt; Ashok Panigrahy; Miguel Reyes-Múgica
Journal:  Neuro Oncol       Date:  2015-09-09       Impact factor: 12.300

3.  BRAF mutations are also associated with neurocutaneous melanocytosis and large/giant congenital melanocytic nevi.

Authors:  Cláudia M Salgado; Dipanjan Basu; Marina Nikiforova; Bruce S Bauer; Donald Johnson; Veronica Rundell; Lorelei J Grunwaldt; Miguel Reyes-Múgica
Journal:  Pediatr Dev Pathol       Date:  2014-12-09

4.  Amplification of mutated NRAS leading to congenital melanoma in neurocutaneous melanocytosis.

Authors:  Cláudia M Salgado; Dipanjan Basu; Marina Nikiforova; Ronald L Hamilton; Robin Gehris; Regina Jakacki; Ashok Panigrahy; Svetlana Yatsenko; Miguel Reyes-Múgica
Journal:  Melanoma Res       Date:  2015-10       Impact factor: 3.599

5.  Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

Authors:  Veronica A Kinsler; Anna C Thomas; Miho Ishida; Neil W Bulstrode; Sam Loughlin; Sandra Hing; Jane Chalker; Kathryn McKenzie; Sayeda Abu-Amero; Olga Slater; Estelle Chanudet; Rodger Palmer; Deborah Morrogh; Philip Stanier; Eugene Healy; Neil J Sebire; Gudrun E Moore
Journal:  J Invest Dermatol       Date:  2013-02-07       Impact factor: 8.551
  5 in total
  2 in total

1.  Response to "Insulin-like growth factor 1 receptor signaling via Akt: a general therapeutic target in neurocutaneous melanocytosis?".

Authors:  Yibing Ruan; Aru Narendran
Journal:  Neuro Oncol       Date:  2016-01       Impact factor: 12.300

2.  The Dual PI3K/mToR Inhibitor Omipalisib/GSK2126458 Inhibits Clonogenic Growth in Oncogenically-transformed Cells from Neurocutaneous Melanocytosis.

Authors:  Dipanjan Basu; Cláudia M Salgado; Bruce Bauer; Yasmin Khakoo; Janki R Patel; Ryan M Hoehl; Dominique M Bertolini; Joie Zabec; Morgan R Brzozowski; Miguel Reyes-Múgica
Journal:  Cancer Genomics Proteomics       Date:  2018 Jul-Aug       Impact factor: 4.069
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.